Oxytrol Switch Should Hinge On Symptom ID, Not Diagnosis – Merck Consultant
This article was originally published in The Tan Sheet
Executive Summary
Merck’s proposed Rx-to-OTC switch of Oxytrol for Women is about identifying symptoms of overactive bladder, not diagnosing the condition, says Eric Brass, former chair of FDA’s Nonprescription Drugs Advisory Committee. Several NDAC members Nov. 9 insisted OAB should be diagnosed before treatment.
You may also be interested in...
NDAC Puts Hitch In Oxytrol Switch With Negative Self-Selection Vote
In a 6-5 vote, FDA’s Nonprescription Drugs Advisory Committee said Merck did not show that consumers can appropriately self-select to use Oxytrol for Women in an OTC setting. The company expects to hear from FDA on its Rx-to-OTC switch application by the end of January.
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin
Prilosec 1 Self-Selected Correctly By 81% Of Actual Use Study Participants
Eighty-one percent of 866 participants in the Prilosec 1 actual use study correctly chose the heartburn medication as appropriate for them to use, Procter & Gamble OTC Drug Development Director Douglas Bierer, PhD, reported (See chart: "1The Prilosec 1 NDA: Take 2")